A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings report with expectations for tighter losses and higher revenue. See our latest analysis for Recursion Pharmaceuticals. Despite the recent 6.17% single day share price decline to US$3.50 and a weaker 1 year total shareholder return of 39.13%, the 10.41% 1 month share price gain hints that sentiment around Recursion's AI driven progress and upcoming earnings has started to recover from a softer 90 day share price return of 26% and year to date share price return of 16.67%. If you like the AI angle in drug discovery but want to see how other names stack up, it is worth scanning 34 healthcare AI stocks With Recursion now trading at US$3.50, a value score of 2 and an estimated 62% intrinsic discount, the key question for you is simple: is this an underappreciated AI drug discovery play, or
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6GlobeNewswire
- Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals May Be Losing Ground To Its Peers [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities [Yahoo! Finance]Yahoo! Finance
- Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form SCHEDULE
- 4/22/26 - Form 144
- RXRX's page on the SEC website